BioCardia vs Senti Biosciences
BCDA and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCDA and SNTI compare
BioCardia is the larger company, worth 2.7 times as much as Senti Biosciences ($12.5M against $4.6M).
BioCardia scores higher on the StockData Score (5 against 4 for Senti Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCDA | SNTI |
|---|---|---|
| Size and price | ||
| Market cap | $12.5M | $4.6M |
| Share price | $0.826 | $0.147 |
| Change, 1 year | −37.9% | −92.0% |
| Change, 5 years | −97.5% | −99.9% |
| Beta (5Y) | 1.00 | 1.84 |
| Employees | 21 | – |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 15.0× | – |
| FCF yield | −60.9% | – |
| Profitability | ||
| Return on equity | −443% (better) | −466% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.11 (better) | 0.83 |
| Altman Z-score | −84.20 | −21.36 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −42.5% | – |
| Shareholder yield | −42.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 8.8% | 18.6% |
| Held by insiders | 11.7% | – |
| Insider net buying, 12 months | $170K | – |
| Short interest, % of float | 5.5% | – |
Go deeper
- BCDA stock overview
- BCDA income statement
- BCDA valuation and score
- SNTI stock overview
- SNTI income statement
- SNTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.